Dyne Therapeutics (DYN) PT Lowered to $12 at Piper Sandler
- Wall Street ends first day of third quarter with solid rebound
- Goldman Sachs Warns Clients of More Equity Market Losses in Second Half of 2022
- Kohl's (KSS) Falls 15% After Ending Sale Talks With Franchise Group and Issuing Q2 Warning
- General Motors Warns It Has 95k Vehicles in Inventory Without Certain Components
- FAAMG Stocks Fall 32% on Average During 1st-Half of 2022
Piper Sandler lowered its price target on Dyne Therapeutics (NASDAQ: DYN) to $12.00 (from $16.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Coupang (CPNG) Market Share to Reach 26% in 2023, Says Analyst
- Medmix AG (MEDX:SW) PT Lowered to CHF37 at UBS
- JPMorgan Downgrades Oil & Natural Gas Corp Ltd. (ONGC:IN) to Neutral
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!